Real-time enrollment status for this hereditary hemorrhagic telangiectasia clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 3:59 PM UTC
| NCT Number | NCT07743671 |
| Recruiting Status | Recruiting |
| Condition | Hereditary Hemorrhagic Telangiectasia |
| Phase | PHASE3 |
| Target Enrollment | 240 participants |
| Active Locations | 4 sites in the US |
| Sponsor | Vaderis Therapeutics AG |
| Last Updated on CT.gov | September 17, 2026 (3 weeks ago) |
As of October 12, 2026: Clinical trial NCT07743671 is currently recruiting participants. This phase3 study for hereditary hemorrhagic telangiectasia is actively seeking new participants at 4 locations across the United States. The study is sponsored by Vaderis Therapeutics AG. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07743671 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 4 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07743671 was last updated 3 weeks ago (September 17, 2026). HelloStudys verifies this status automatically.